Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1810 - Clinical Outcome and Prognostic Factors for Patients Treated in a Phase I Study at the National University Cancer Institute, Singapore (NCIS) (138P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Clinical Research


Cheng Ean Chee


Annals of Oncology (2017) 28 (suppl_10): x39-x41. 10.1093/annonc/mdx658


C.E. Chee1, R. Soo1, B. Goh1, W.P. Yong1, S.C. Lee1, D.S. Tan1, A. Wong1, W.J. Chng1, V. Heong1, B.C. Tai2

Author affiliations

  • 1 Haematology-oncology, National University Cancer Institute Singapore, 119074 - Singapore/SG
  • 2 Epidemiology, NUS Saw Swee Hock School of Public Health, 117549 - Singapore/SG


Abstract 1810


Patient selection for phase I trials in oncology is challenging. A typical inclusion criterion for phase I studies is 'life expectancy >3 months', however overall survival (OS) of patients with advanced solid malignancies are difficult to predict. Other studies have demonstrated that despite the use of traditional eligibility criteria for enrollment into a Phase I (P1) study, about 1/3 of patients fail to meet all the necessary eligibility criteria at screening and ∼15-20% die within the first 90 days of P1 trial entry. The P1 Unit at the Royal Marsden Hospital (RMH), UK has found that a prognostic score is a helpful tool in the process of patient selection for P1 trial entry. We aim to develop a similar prognostic score predicting OS in our P1 patient population here at the NCIS.


Patients in P1 studies completed between Oct. 2013 – Jan. 2016 at NCIS and had EMR available were reviewed. Patient characteristics and survival data were analysed.


120 pts from 10 completed P1 studies were included. Median age was 44.5 years (range: 23-79). Baseline variables were: age >60 (56%), male (53%), ECOG 0-1 (98%), comorbidities ≥2 (26%), no. of prior therapies ≥3 (65%), no. of metastatic sites ≥3 (40%). Univariate analysis revealed that albumin 2 sites) was also at the threshold of significance (HR: 1.62, 95% CI: 0.99 – 2.64, p 


Risk scoring based on objective clinical parameters indicated that patients with a high score had a significantly shorter OS and this may assist in the selection of patient entry into P1 studies. A prospective study will be needed to test the validity of the prognostic score.

Legal entity responsible for the study

National University Cancer Institute, Singapore

Clinical trial identification

Legal entity responsible for the study

National University Cancer Institute, Singapore


National University Cancer Institute, Singapore


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.